Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q2 2017 (← Previous) (Next →)

Filing Date: Aug 14, 2017

Total Value ($000): $299,557 (100.0% shares, 0.0% debt)

Holdings (8)

BIIB BIOGEN INC 34.8%

Value ($000) $104,163 Shares 383,858 Est. Cost $282.94 Unrealized -6.5%

— BIOVERATIV INC 23.4%

Value ($000) $70,098 Shares 1,165,000 Est. Cost $60.17 Unrealized —

— MEDICINES CO 22.2%

Value ($000) $66,593 Shares 1,752,000 Est. Cost $29.63 Unrealized —

INVA INNOVIVA INC 14.9%

Value ($000) $44,681 Shares 3,490,705 Est. Cost $11.04 Unrealized +13.7%

— NOVELION THERAPEUTICS INC 3.2%

Value ($000) $9,460 Shares 1,025,000 Est. Cost $8.42 Unrealized —

— ADVAXIS INC 0.7%

Value ($000) $2,201 Shares 339,180 Est. Cost $8.09 Unrealized —

— APRICUS BIOSCIENCES INC 0.5%

Value ($000) $1,636 Shares 1,447,906 Est. Cost $1.30 Unrealized —

ABBV ABBVIE INC. 0.2%

Value ($000) $725 Shares 10,000 Est. Cost $38.85 Unrealized +20.9%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
BIIB	BIOGEN INC	383,858	$104,163	34.8%	$282.94	-6.5%	COM	09062X103
—	BIOVERATIV INC	1,165,000	$70,098	23.4%	$60.17	—	COM	09075r100
—	MEDICINES CO	1,752,000	$66,593	22.2%	$29.63	—	COM	584688105
INVA	INNOVIVA INC	3,490,705	$44,681	14.9%	$11.04	+13.7%	COM	45781M101
—	NOVELION THERAPEUTICS INC	1,025,000	$9,460	3.2%	$8.42	—	COM NEW	67001K202
—	ADVAXIS INC	339,180	$2,201	0.7%	$8.09	—	COM NEW	007624208
—	APRICUS BIOSCIENCES INC	1,447,906	$1,636	0.5%	$1.30	—	COM NEW	03832V307
ABBV	ABBVIE INC.	10,000	$725	0.2%	$38.85	+20.9%	COM	00287Y109